Gainers

  • AVITA Medical (NASDAQ:RCEL) stock rose 58.4% to $7.53 during Friday's regular session. The company's market cap stands at $146.1 million. As per the press release, Q2 earnings came out yesterday.
  • Embecta (NASDAQ:EMBC) stock moved upwards by 32.42% to $4.63. The market value of their outstanding shares is at $207.2 million. As per the news, the Q3 earnings report came out today.
  • Starling Oncology (NASDAQ:STLN) shares rose 32.06% to $6.59. The market value of their outstanding shares is at $498.9 million.
  • Doximity (NYSE:DOCS) shares moved upwards by 31.65% to $27.2. The company's market cap stands at $3.7 billion. The company's, Q1 earnings came out yesterday.
  • Senseonics Holdings (NASDAQ:SENS) stock rose 24.85% to $6.43. The market value of their outstanding shares is at $268.8 million. The company's, Q2 earnings came out yesterday.
  • OmniAb (NASDAQ:OABI) shares moved upwards by 22.37% to $2.74. The company's market cap stands at $324.7 million. The company's, Q2 earnings came out yesterday.

Losers

  • CVRx (NASDAQ:CVRX) stock declined by 57.8% to $2.5 during Friday's regular session. The company's market cap stands at $157.6 million. The company's, Q2 earnings came out yesterday.
  • Organogenesis Holdings (NASDAQ:ORGO) stock decreased by 29.88% to $1.69. The market value of their outstanding shares is at $310.1 million. As per the news, the Q2 earnings report came out yesterday.
  • BioVie (NASDAQ:BIVI) stock decreased by 25.12% to $1.01. The company's market cap stands at $10.1 million.
  • Health Catalyst (NASDAQ:HCAT) stock declined by 24.9% to $1.74. The company's market cap stands at $170.6 million. The company's, Q2 earnings came out yesterday.
  • QuidelOrtho (NASDAQ:QDEL) shares fell 23.04% to $12.56. The company's market cap stands at $1.1 billion. As per the press release, Q2 earnings came out yesterday.
  • Autonomix Medical (NASDAQ:AMIX) shares fell 20.34% to $9.7. The company's market cap stands at $6.5 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.